Interviewing Brian Culley on Lineage Cell Therapeutics
2020 is the decade of the cell. The next 10 to 20 years are going to be huge for developing cell-based treatments and no one is a better guide into the world of this research than Brian Culley, the CEO of Lineage Cell Therapeutics, a company making enormous strides using pluripotent stem cells
Extending the Health Span of Our Pets & It’s Impact On Human Longevity
Nick Sinclair is the CEO of Animal Biosciences, a biotech company working toextend the healthy lifespan of pets and companion animals. It is a member of the Life Biosciences family. Nick Sinclair has had a very varied career so far. How has he gotten where he is today?
Interviewing Joseph Baur, on NAD, NMN and NR
There is an enormous amount of confusing information out there about NAD and in today’s interview, Joseph Bower, one of the world’s leading NAD researchers helps to clear up some of these age old questions. What’s better NMN versus NR. At what age should I begin taking an NAD precursor is injection more effective than oral supplementation. Joseph helps answer all these questions and a lot more. So if you’ve been extremely confused, just like I was NMN, NR and especially NAD, then this interview is for you.
Interviewing Gregory Bailey, CEO of Juvenescence, on Investing in Longevity
Dr. Greg Bailey is the CEO of Juvenescence, one of the largest biotech drug developers working on anti-aging and longevity research to extend healthy lifespan.This will be the greatest investment opportunity in all of human history. We will start to see small gains in the next few years, with bigger impacts in stages. Most of the treatments are about prevention rather than treatment.
Alex Zhavoronkov of Insilico Medicine – Artificial Intelligence for Drug and Bio Marker Discovery – Simple BioTech Podcast #5
Dr. Alex Zhavaronkov is the CEO of Insilico Medicine, a biotech company using artificial intelligence for drug and biomarker discovery. Dr. Zhavaronkov wants to use this company and the technology they are developing to increase the number of drugs for aging all the way through the process of clinical trials, currently an arduous and expensive process.